Helix BioPharma Corp (TSX:HBP) (OCTMKTS:HBPCF) announced Thursday that topline data from a recent L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in non-squamous non-small cell lung cancer will be published at the ASCO 2020 annual conference.
“We are very optimistic with L-DOS47’s demonstrated excellent safety profile and encouraging efficacy data,” said CEO Dr Heman Chao in a statement.
Helix said the Phase 1 dose escalation study involved 14 patients with recurrent or metastatic non-squamous non-small cell lung cancer enrolled across six dosing cohorts, and that no dose limiting toxicities were observed.
READ: Helix BioPharma maintaining business continuity amid coronavirus pandemic
Of the 12 patients evaluated for efficacy, five patients (41.7%) had a partial response, four patients (33.3%) experienced stable disease and three patients (25%) had progressive disease.
Helix said the objective response rate was 41.7% and the clinical benefit rate 75.0%, noting that L-DOS47 appeared to be well tolerated with promising anti-tumor activity.
“I would like to thank the patients and their families who participated in our clinical study, as well as the principal investigators and associates who helped conduct the study,” said Dr Chao.
The ASCO conference will be held virtually from May 29-31
Shares in Toronto nudged up 3.31% to C$1.25.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
